Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up after Autolus CAR T cell therapies
2016-004867-38Phase 2Unknown
- Sponsor
- Autolus Therapeutics plc
- Start
- Dec 2017
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of obecabtagene autoleucel, AUTO2, AUTO3 and AUTO4 in cancer and secondary malignancy (4 arms), sponsored by Autolus Therapeutics plc. Primary endpoint: Incidence of serious adverse events. Status: unknown.
02
Drugs
obecabtagene autoleucelAUTO2AUTO3AUTO4
03
Conditions
cancersecondary malignancy
Beyond the preview
Go deeper on 2016-004867-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004867-38.